OXCARBAZEPINE
OXCARBAZEPINE is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: OXCARBAZEPINE; Generic name: OXCARBAZEPINE; Drug class: Anti-epileptic Agent [EPC].
| Brand name | OXCARBAZEPINE |
|---|---|
| Generic name | OXCARBAZEPINE |
| Drug class | Anti-epileptic Agent [EPC] |
| Manufacturer | NorthStar RxLLC |
| Used for | 1 INDICATIONS AND USAGE Oxcarbazepine oral suspension is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures. Oxcarbazepine oral suspension is indicated for: • Adults: Monotherapy or adjunctive therapy in the treatment of partial-onset seizures • Pediatrics: - Monotherapy in the treatment of partial-onset seizures in children 4 to 16 years - Adjunctive therapy in the treatment of partial-onset seizures in children 2 to 16 years (1) |
| Dosage | 2 DOSAGE AND ADMINISTRATION Adults : initiate with a dose of 600 mg/day, given twice a day • Adjunctive Therapy: Maximum increment of 600 mg/day at approximately weekly intervals. The recommended daily dose is 1200 mg/day ( 2.1 ) • Conversion to Monotherapy: Withdrawal concomitant over 3 to 6 weeks; reach maximum dose of oxcarbazepine oral suspension in 2 to 4 weeks with increments of 600 mg/day at weekly intervals to a recommended daily dose of 2400 mg/day ( 2.2 ) • Initiation of Monotherapy: I |
| Active ingredient(s) | OXCARBAZEPINE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1746d95f-c529-45ba-a520-0c135e8edda8 |